Resultats de la cerca - Naveen Pemmaraju

Refinar resultats
  1. 1
    Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm

    Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm per Naveen Pemmaraju, Marina Konopleva

    Publicat 2020
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    FLT3 inhibitors in the treatment of acute myeloid leukemia

    FLT3 inhibitors in the treatment of acute myeloid leukemia per Naveen Pemmaraju, Hagop M. Kantarjian, Farhad Ravandi, Jorge E. Cortés

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects

    Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects per Naveen Pemmaraju, Mark F. Munsell, G. N. Hortobagyi, Sharon H. Giordano

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  4. 4
    Social Media and the Adolescent and Young Adult (AYA) Patient with Cancer

    Social Media and the Adolescent and Young Adult (AYA) Patient with Cancer per Miguel‐Angel Perales, Emily K. Drake, Naveen Pemmaraju, William A. Wood

    Publicat 2016
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  5. 5
    Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy

    Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy per Naveen Pemmaraju, Prithviraj Bose, Raajit K. Rampal, Aaron T. Gerds, Angela Fleischman, Srđan Verstovšek

    Publicat 2023
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  6. 6
    Erythroleukemia-historical perspectives and recent advances in diagnosis and management

    Erythroleukemia-historical perspectives and recent advances in diagnosis and management per Prajwal Boddu, Christopher B. Benton, Wei Wang, Gautam Borthakur, Joseph D. Khoury, Naveen Pemmaraju

    Publicat 2017
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  7. 7
    Is acute myeloid leukemia a liquid tumor?

    Is acute myeloid leukemia a liquid tumor? per Maro Ohanian, Stefan Faderl, Farhad Ravandi, Naveen Pemmaraju, Guillermo Garcia‐Manero, Jorge E. Cortés, Zeev Estrov

    Publicat 2013
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  8. 8
    Real-world treatments and thrombotic events in polycythemia vera patients in the USA

    Real-world treatments and thrombotic events in polycythemia vera patients in the USA per Srđan Verstovšek, Naveen Pemmaraju, Nancy L. Reaven, Susan E. Funk, Tracy Woody, Frank H. Valone, Suneel Gupta

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia

    Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia per Naveen Pemmaraju, Aaron T. Gerds, Jingbo Yu, Shreekant Parasuraman, Anne Shah, Ann Xi, Shambhavi Kumar, Robyn M. Scherber, Srđan Verstovšek

    Publicat 2022
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis

    Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis per Lucia Masárová, Ahmad Alhuraiji, Prithviraj Bose, Naval Daver, Naveen Pemmaraju, Jorge E. Cortés, Sherry Pierce, Hagop M. Kantarjian, Srđan Verstovšek

    Publicat 2017
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Sex differences in the JAK2V617F allele burden in chronic myeloproliferative disorders

    Sex differences in the JAK2V617F allele burden in chronic myeloproliferative disorders per Barry Stein, Donna M. Williams, Nae‐Yuh Wang, Ophelia Rogers, Mark A. Isaacs, Naveen Pemmaraju, Jerry L. Spivak, Alison R. Moliterno

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis

    Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis per Lucia Masárová, Prithviraj Bose, Naval Daver, Naveen Pemmaraju, Kate J. Newberry, Taghi Manshouri, Jorge E. Cortés, Hagop M. Kantarjian, Srđan Verstovšek

    Publicat 2017
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Improved survival of patients with myelofibrosis in the last decade: Single‐center experience

    Improved survival of patients with myelofibrosis in the last decade: Single‐center experience per Lucia Masárová, Prithviraj Bose, Naveen Pemmaraju, Naval Daver, Koji Sasaki, Helen T. Chifotides, Lingsha Zhou, Hagop M. Kantarjian, Zeev Estrov, Srđan Verstovšek

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN)

    Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN) per Hannah C. Beird, Maliha Khan, Rui Wang, Mansour Alfayez, Tianyu Cai, Li Zhao, Joseph D. Khoury, P. Andrew Futreal, Marina Konopleva, Naveen Pemmaraju

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Defining disease modification in myelofibrosis in the era of targeted therapy

    Defining disease modification in myelofibrosis in the era of targeted therapy per Naveen Pemmaraju, Srđan Verstovšek, Ruben A. Mesa, Vikas Gupta, Jacqueline S. Garcia, Joseph M. Scandura, Stephen T. Oh, Francesco Passamonti, Konstanze Döhner, Adam J. Mead

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  16. 16
    Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper From an Ad Hoc International Expert Panel

    Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper From an Ad Hoc International Expert Panel per Livio Pagano, Pier Luigi Zinzani, Stefano Pileri, Pietro Quaglino, Branko Cuglievan, Emilio Berti, Naveen Pemmaraju, Francesco Onida, Rein Willemze, Alberto Órfão, Giovanni Barosi

    Publicat 2023
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy

    Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy per Naveen Pemmaraju, Hagop M. Kantarjian, Loretta J. Nastoupil, Megan Dupuis, Lisa Zhou, Sherry Pierce, Keyur P. Patel, Lucia Masárová, Jorge E. Cortés, Srđan Verstovšek

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  18. 18
    Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase

    Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid... per Talha Badar, Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Gautam Borthakur, Jorge E. Cortés, Naveen Pemmaraju, Sherry R. Pierce, Kate J. Newberry, Naval Daver, Srđan Verstovšek

    Publicat 2015
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Final results of a phase 2, open‐label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome

    Final results of a phase 2, open‐label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic s... per Rita Assi, Hagop M. Kantarjian, Tapan M. Kadia, Naveen Pemmaraju, Elias Jabbour, Nitin Jain, Naval Daver, Zeev Estrov, Taisuke Uehara, Takashi Owa, Jorge E. Cortés, Gautam Borthakur

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm

    Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual... per Wei Wang, Joseph D. Khoury, Roberto N. Miranda, Jeffrey L. Jorgensen, Jie Xu, Sanam Loghavi, Shaoying Li, Naveen Pemmaraju, Than Nguyen, L. Jeffrey Medeiros, Sa A. Wang

    Publicat 2020
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: